ライフサイエンスコーパス: false-negative

1 orted as being disease-free on FDG-PET ("PET false-negative").

2 inds of errors exist, 'false positives' and 'false negatives'.

3 rasound did not detect a retinal detachment (false-negative).

4 se positives) or completeness (low number of false negatives).

5 ion despite pathologic confirmation of aGCM (false negatives).

6 tured by experiments on a rodent population (false negatives).

7 I in the postinterventional setting is often false-negative.

8 tive scans for primary tumor were considered false-negative.

9 UK) in false positives and 9.4% and 2.7% in false negatives.

10 o adopt statistical approaches to also limit false negatives.

11 ductions of 11% in false positives and 5% in false negatives.

12 full potential of chemical libraries due to false negatives.

13 t sensitivity and minimize the likelihood of false negatives.

14 sider, which can lead to false positives and false negatives.

15 of patients while 40% remained diagnosed as false negatives.

16 n loss, 15% for false-positives, and 33% for false-negatives.

17 False-negative (124)I PET/CT results as compared with po

18 However, false-negative (124)I PET/CT results as compared with po

19 ffected by high rates of false positives and false negatives(2).

20 6) of artifacts masked true progression (ie, false-negative), 36.5% (35/96) led to an interpretation

21 that snoReport 2.0 avoid false positives and false negatives, allowing to predict snoRNAs with high q

22 at specificity, but are affected by moderate false negative and missing value rates.

23 ing agents, including those known to produce false negative and positive results.

24 e that the benchmark set reliably identifies false negatives and false positives in high-quality SV c

25 f patients with solid malignancies; however, false negatives and false positives remain major limitat

26 FDG-PET/CT resulted in no false negatives and fewer false positives than the other

27 ged by their intrinsic diversity, leading to false negatives and incomplete characterisation.

28 ed diagnosis, which have been found prone to false negatives and misdiagnoses, respectively.

29 include onboard positive controls to reduce false negatives and specialized hardware to enable real-

30 improved library still has library-specific false negatives and, for the first time, estimated the f

31 e/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test res

32 To minimise false-negative and false-positive classifications, recom

33 Overall false-negative and false-positive fractions were 22% and

34 ved benchmark set for identification of both false-negative and false-positive germline large inserti

35 sensitivity and specificity (>90%), but the false-negative and false-positive rates makes the test s

36 have been misinterpreted, reviews causes of false-negative and false-positive results, and provides

37 To explore reasons for false-negative and/or false-positive results, we used pf

38 high degree of fidelity and low rate of both false-negatives and false-positives in this approach.

39 eg raising test was negative in 15 patients (false negatives) and positive in six patients (true posi

40 diagnosed between surveillance assessments (false negatives) and two biopsied lesions were non-neopl

41 mal tests in conditions other than syphilis, false negatives, and automated nontreponemal tests.

42 The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primar

43 To minimize false-negative BC results for patients already receiving

44 ssible to significantly reduce the number of false-negative biopsies.

45 signal in the primary motor cortex (PMC), as false-negative blood oxygen level-dependent (BOLD) funct

46 strategy resulted in fewer QALYs due to more false negatives but an ICER of $3,012, making this strat

47 site of interest is displaced; it mitigates false negatives by detecting a reporter compound that io

48 ttings, resulting in high false-positive and false-negative calls.

49 is, was significantly lower expressed in PET false-negative cases (5.3-fold change, P < .001) which p

50 ogic correlation although false-positive and false-negative cases exist.

51 g appropriate antimicrobial therapy, with no false-negative cases.

52 of in vitro results by identifying possible "false negatives." CITATION: Phillips MB, Leonard JA, Gru

53 artly responsible for the false positive and false negative compound identifications.

54 sequencing studies, we propose the Adaptive False-Negative Control (AFNC) procedure that can include

55 imal biological sampling as a contributor to false-negative COVID-19 test results and underscore the

56 s was performed to assess factors related to false negative CXR.

57 CXR findings were the largest factor behind false-negative CXRs (40% normal and 87% combined normal/

58 ease this probability, resulting in delayed (false-negative) declarations.

59 Thirteen (5.3%) false-negative tears and no false-negative detachments were identified.

60 l misclassification was observed in terms of false negatives detected after the incorporation of infa

61 reduce filter clogging, PCR inhibition, and false-negative detections when eDNA is at low concentrat

62 There were 10 false-positive and four false-negative detections with the Aries assay.

63 in improved diagnostic confidence and lower false-negative diagnoses.

64 The rate of false negative discordance was 8.6%.

65 alls, but this does not ameliorate potential false negatives due in part to evaluating a limited pane

66 g but at the cost of potentially introducing false negatives due to suppression of specific interacti

67 minimizing a linear combination of potential false negatives (due to allele dropout or variance in se

68 ll have many false positive interactions and false negative edge loss due to the limitations of high-

69 and the type 1 (false-positive) and type 2 (false negative) error rates of the experiments designed

70 In particular, the false negative errors restrict the search space of such

71 method that accounts for false-positive and false-negative errors to test deer saliva for chronic wa

72 (95% CI, 4.2 to 19.8), which included seven false-negative events in 69 patients with residual disea

73 al muscular dystrophies, and 21 patients had false-negative findings for DMD.

74 set, the algorithm identified 34 of 71 (48%) false-negative findings on mammograms.

75 The false-negative findings were caused by uncommon rifampic

76 -RADS resulted in nine false-positive and 16 false-negative findings, whereas VRC with a 5% threshold

77 reshold resulted in 29 false-positive and 10 false-negative findings.

78 (-1) for probabilities of false positive and false negative fixed at 0.05.

79 Accordingly, false negative (FN) (81% Singapore and all NZ FN cases w

80 and/or tumor characteristics associated with false negative (FN) AUS.

81 that were recorded as false positive (FP) or false negative (FN) compared to the reference method.

82 ion) and 78 were categorized as potential OC false-negative (FN) findings.

83 e-positive (FP) or 'type I error' cases, and false-negative (FN) or 'type II error' cases were ascert

84 False-negative (FN) screening examinations can be a surr

85 s performed for 24 false-positive (FP) and 3 false-negative (FN) specimens.

86 of the test reliability, as indicated by the false-negative (FN), false-positive (FP), and fixation l

87 ata sets, including false-positives (FP) and false-negatives (FN) due to allelic dropout, and cell do

88 Assess the impact of false-positives (FP), false-negatives (FN), fixation losses (FL), and test dur

89 been successfully validated with respect to false negatives for the sum PCB 28, 52, 101, 138, 153 an

90 s; however, all 3 readers had an increase in false-negatives for 1/3-dose images compared with full-d

91 Using IDF criteria, there were high false-negative fractions for both systolic and diastolic

92 eement, with most discordance arising due to false-negative GM-EIA samples that were positive by LFA.

93 Four of the 6 false negatives had large subretinal hemorrhage (SRH) an

94 Eleven of these false-negatives had an associated hemothorax and 6 had p

95 Indeed, false positive and false negative HRMS detections are rare, albeit possible

96 vity with human and porcine fVIII leading to false-negative HSM results.

97 n of potential sources of false-positive and false-negative HTR events.

98 ional requirement while not introducing many false negatives (i.e. omitting to report a valid alignme

99 ans in N0 necks was true negative in 87% and false negative in 13%.

100 oaches for mitigation of false positives and false negatives in dPCR.

101 coreference resolution are a common cause of false negatives in information extraction from the scien

102 Because of detection of potential false negatives in that cohort, the NAAT results of pair

103 anual abstraction by >=90%, resulting in <1% false negatives in the "negative" group and a sensitivit

104 lation, with evidence of false positives and false negatives in the microarray data.

105 igh risk of misclassification, mostly due to false negatives in younger subjects.

106 (18)F-FDG PET/CT was false-negative in all cases with infected NV.

107 a indicate that LTBI screening is frequently false-negative in this patient population, likely due to

108 LTBI screening is frequently false-negative in this patient population, likely due to

109 high likelihoods of both false-positive and false-negative inferences.

110 by reducing the number of false positive and false negative interactions and is better optimized to p

111 Artifacts can lead to false-positive and false-negative interpretation of progression when using

112 e fetal CNV and that at least one of the two false negatives is due to a low fetal fraction.

113 -seq and RNAcompete, usually suffer from the false negative issue.

114 I-RADS) version 2 score to better understand false-negative lesion characteristics.

115 women at transvaginal US, and three of five false-negative lesions were microscopic or very small.

116 e a relevant number of patients with FDG-PET false-negative MM and a strong association between hexok

117 emographic differences between patients with false-negative MP MR imaging findings and those with cor

118 tumor samples can prevent false-positive and false-negative mutation detection to improve diagnosis.

119 Two-hundred thirty-three false-negative OFOQ results occurred in 80 of 287 seroco

120 ntiretroviral therapy was observed to have a false negative OMT result, from July 2015 urine samples

121 Seven isolates were identified as false negative on the basis of the RDTs results.

122 ed in LFA, provides a highly sensitive (zero false negatives on 50 hERG-sensitive drugs) and highly s

123 Any false negative or positive results could lead to severe

124 s under which conventional testing may yield false-negative or otherwise uninterpretable results, inc

125 eutic strategy based on what are essentially false-negative outcomes.

126 using dHRM analysis reduces the inclusion of false-negative partitions, changing the calculated DNA c

127 de a practical and timely approach to reduce false-negative patient stratification for guiding anti-P

128 -positive, true-negative, false-positive and false-negative patients as classified against any refere

129 The primary endpoint was the proportion of false-negative patients with tumor regression grade (TRG

130 False positive and false negative peaks detected from extracted ion chromat

131 In no case do we make a false negative prediction; for chlorine, bromine, boron,

132 n issued guidance on investigating suspected false-negative rapid diagnostic tests (RDTs) due to pfhr

133 the hospital, due to poor assay performance, false-negatives, rapid drug clearance rates, and difficu

134 te (incorrect neoantigens predicted) and the false negative rate (strong-binding neoantigens missed)

135 We consider the false negative rate acceptable for routine clinical use;

136 superior to C. elegans based on both reduced false negative rate and superior overall quality of acti

137 er primary chemotherapy because the high SNB false negative rate might lead to poorer outcomes.

138 andard kits and protocols, with an estimated false negative rate of 10%.

139 ptimization of XCMS parameters can lead to a false negative rate of up to 80% for chemicals spiked at

140 e rate of repeat exams (within 1 wk) and the false-negative rate (defined as diagnosis of venous thro

141 n and removal of clipped nodes, improves the false-negative rate (FNR) compared with SLND alone.

142 rgeons Oncology Group Z1071 trial reported a false-negative rate (FNR) of 12.6% with sentinel lymph n

143 n endpoints were the detection rate (DR) and false-negative rate (FNR) of TLNB and TAD after NST.

144 The primary endpoint was the false-negative rate (FNR) of VAB-confirmed pCR-B.

145 formed to compare identification rate (IFR), false-negative rate (FNR), and negative predictive value

146 ificant difference in biopsy rate (P = .54), false-negative rate (P = .38), cancer detection rate (P

147 important, and new approaches to reduce this false-negative rate are needed.

148 ierarchical model was fitted to estimate the false-negative rate by day since exposure and symptom on

149 The false-negative rate for CO-RADS 1 was nine of 161 cases

150 Within the RAVEN cohort, the expected false-negative rate for detection at lower rep numbers u

151 risk for future breast cancer, with a lower false-negative rate for more aggressive cancers.

152 a history of asthma associated with a higher false-negative rate for VQ (asthma, 0.4%; nonasthma, 0.9

153 inoma and a tumor-negative neck US, the high false-negative rate of (124)I PET/CT after recombinant h

154 ation was 66.4% (95% CI, 62.8%-69.9%) with a false-negative rate of 2%.

155 The higher analytic sensitivity and lower false-negative rate of HTS improves upon FC for MRD dete

156 As a result of the 30% false-negative rate of plasma genotyping, those with T79

157 As the false-negative rate of SLNB correlates with the number o

158 The false-negative rate of the Accula POC test calls for a m

159 Sensitivity and false-negative rate of the IRIS computer-based algorithm

160 ; specificity, 88.9% (95% CI: 88.8%, 88.9%); false-negative rate per 1000 screens, 0.8 (95% CI: 0.7,

161 etection rate (CDR) per 1000 women screened, false-negative rate per 1000 women screened, positive pr

162 ded if the false-positive rate was <=20% and false-negative rate was <=35%.

163 The false-negative rate was 35% (14.2% [two of 14] of patien

164 On the day of symptom onset, the median false-negative rate was 38% (CI, 18% to 65%).

165 The false-negative rate was lower: 31% (95% CI: 29%, 34%), 3

166 formed (PPV3), 30.4% (95% CI: 29.9%, 30.9%); false-negative rate, 4.8 per 1000 (95% CI: 4.6, 5.0); se

167 1.24]; negative LR, 0.06 [CI, 0.04 to 0.09]; false-negative rate, 5%; false-positive rate, 11%).

168 4.55]; negative LR, 0.07 [CI, 0.04 to 0.11]; false-negative rate, 5%; false-positive rate, 24%).

169 the reported affinity accuracy, reduces the false-negative rate, and increases the amount of useful

170 Recall rate, biopsy rate, false-negative rate, cancer detection rate, positive pre

171 ing program had a high sensitivity and a low false-negative rate, suggesting that it may be an effect

172 e rate at the expense of a small increase in false-negative rate.

173 tives and, for the first time, estimated the false negative rates of CRISPR-KO screens, which are bet

174 figures of merit, such as false positive and false negative rates, selectivity, specificity and effic

175 se tools suffer from high false positive and false negative rates.

176 of prostate needle biopsies, which have high false negative rates.

177 this test has substantial false positive and false negative rates.

178 curacy and reduced false positive as well as false negative rates.

179 ch for stem-loop structures, leading to high false negative rates.

180 was assessed in terms of false positive and false negative rates.

181 age and African-American ethnicity increased false negative rates.

182 removal of VFs with high false-positive and false-negative rates and entries with missing data-were

183 g results with much lower false-positive and false-negative rates especially with a high multiplicity

184 False-negative rates were obtained for the DL risk score

185 False-negative rates were slightly lower for DBT (0.6 pe

186 ader variability and high false-positive and false-negative rates(7-10).

187 losses, <30% false-positive rates, and <30% false-negative rates) were recruited.

188 ecommendations; harms (false-positive rates, false-negative rates, surgery rates).

189 ver e-cigarette use), indicating substantial false-negative rates.

190 ure of sample quality that could help reduce false-negative rates.

191 There were no false-negative ratings.

192 asmodium falciparum hrp2 (pfhrp2) gene cause false-negative RDT results and have never been investiga

193 However, false-negative RDT results were identified and can under

194 False-negative RDT results with high parasitemia could b

195 the number of antimalarial treatments due to false-negative RDT results.

196 r methods and predict that the prevalence of false-negative RDTs due to pfhrp2/3 deletions is highest

197 However, pfhrp2 gene deletions yielding false-negative RDTs, first reported in South America in

198 ternal amplification controls to account for false-negative reactions and amplicon high-resolution me

199 ed negative OFOQ results as true-negative or false-negative relative to nucleic acid amplification te

200 " make it far too easy to obtain and publish false-negative replication results, even while appearing

201 The absence of false negatives reported here opens up the possibility o

202 , and may explain an important proportion of false-negative resistance determinations.

203 The sample with a false-negative result by CrAgSQ (n = 1) had a titer of <

204 ctiae, there was a single false-positive and false-negative result each, for a sensitivity and specif

205 as B. pertussis by the FilmArray RP and one false-negative result for both the Aries BA and the Film

206 symptom onset (day 5), the probability of a false-negative result in an infected person decreases fr

207 In 19 of the 37 cases (51.4%), the false-negative result was potentially avoidable.

208 m(2) and eGFR >= 50 ml/min/1.73m(2) (i.e. a "false negative" result when only determining eGFR).

209 y be required to rule out the possibility of false negative results and there is currently a shortage

210 identify diagnoses of non-DMD disorders and false negative results from 1975 to July 12, 2015.

211 rovides a mathematical approach to limit the false negative results occuring with the use of other no

212 ting utility in mitigating false positive or false negative results of direct SARS-CoV-2 tests.

213 ariance, and thus lead to false positive and false negative results when the number of non-zero value

214 roiliitis diagnoses (both false positive and false negative results).

215 er, these criteria can lead to high rates of false negative results, FN.

216 as an indicator of acute stress is prone to false negative results, increasing in some stressful sit

217 ture with one of these compounds, leading to false negative results.

218 true-negative, zero false-positive, and zero-false negative results.

219 clinical implications of false positive and false negative results.

220 e to catalyze the reverse direction to avoid false negative results.

221 assays, BiFC can produce false positive and false negative results.

222 Rates of false-negative results (1.0 to 1.5 per 1000 women) and r

223 VF had fixation losses (FLs) of 33% or less, false-negative results (FNRs) of 20% or less, and false-

224 .63-0.99) presented the lowest proportion of false-negative results (low certainty in the evidence).

225 ing recurrent or persistent EMPD; causes for false-negative results according to their location, hist

226 ities <100/muL, which accounted for 75.7% of false-negative results and 33.3% of PCR-detectable infec

227 by using MR imaging may thus help to reduce false-negative results and improve risk assessment.

228 equations to examine the association between false-negative results and participant, clinical, and te

229 Rates of false-positive and false-negative results and recommendations for additiona

230 l mammography may receive false-positive and false-negative results and subsequent imaging and biopsi

231 st needle by volume (7-gauge) resulted in no false-negative results and that combining imaging and im

232 These programs will need to be aware that false-negative results are a possibility.

233 Rates of false-negative results are low.

234 Moreover, false-positive or false-negative results can occur.

235 erences in resting-state connectivity may be false-negative results driven by a neurovascular uncoupl

236 The pitfalls involve potential false-negative results due to blurring or missing lesion

237 ed to an overestimation of response (yielded false-negative results for residual disease) in 66.7% (1

238 test performance and factors contributing to false-negative results in longitudinal studies, we exami

239 and 96%, depending on the unknown number of false-negative results in single-tested patients.

240 IPDA over standard PCR assays which generate false-negative results in such situations.

241 However, the risk of PET false-negative results in the presence of carbidopa is a

242 The CryptoPS false-negative results included samples with titers of <

243 False-negative results occurred in patients with PTLD in

244 False-negative results were confirmed in the Waldeyer's

245 er of true- and false-positive and true- and false-negative results were extracted to fit a cross-tab

246 False-negative results were found in 2 patients and occu

247 No false-negative results were found.

248 All (16/16) CryptoPS false-negative results were obtained for samples with IM

249 g four marker peptides, no false-positive or false-negative results were obtained.

250 vel parasitemia, and PfHRP-II tests can give false-negative results when P. falciparum strains do not

251 There were 49 cases of RDT false-negative results with a parasite density range of

252 Seven of the 1982 patients (0.4%) had false-negative results with the staged algorithm.

253 The AST systems showed false-negative results with varying numbers, misidentify

254 ters (including the clinical implications of false-negative results), the exclusion of transmission e

255 had pre-existing PVD at the time of surgery (false-negative results).

256 problems associated with false-positive and false-negative results, inconsistencies and low reactivi

257 sociated morbidity, fewer false-positive and false-negative results, lower-cost, and higher analytica

258 re likely to produce both false-positive and false-negative results, resulting in an inaccurate and i

259 on that could help exclude false-positive or false-negative results.

260 r antimicrobial resistance genes can lead to false-negative results.

261 clinical implications of false-positive and false-negative results.

262 ex, and HIV subtype were not associated with false-negative results.

263 resulting in increases in false-positive and false-negative results.

264 es result in weak antibody binding and cause false-negative results.

265 of false-positive results without generating false-negative results.

266 dies, potentially causing false-positive and false-negative results.

267 decrease in the test line (T) intensity and false-negative results.

268 ign did not ensure complete ascertainment of false-negative results.

269 e threshold 8-OHdG value that would minimize false-negative results.

270 Regarding "false negative" results, this possibility maybe verified

271 fferentiation of highly positive samples and false-negative samples and can indicate whether the LFIA

272 The percentages of "false negative" samples were equal to 23.3% for indirect

273 egative; there were 14 false-positive and 29 false-negative scans.

274 clinical tools to reduce false positive and false negative screening mammography results.

275 The observed false-negative screening results also underline that BM

276 ogenicity, host factors, vaginal microbiome, false-negative screening, and/or changes in antibiotic r

277 nt had better control of false positives and false negatives (sensitivity = 0.89, specificity = 0.91,

278 False-negative severe acute respiratory syndrome coronav

279 False-negative SLNB results were reported in 5 articles

280 The one false-negative specimen was from a patient with a pseudo

281 All 4 false-negative stx1 or stx2 results were reported for fr

282 Thirteen (5.3%) false-negative tears and no false-negative detachments w

283 s based on high-risk characteristics, and no false-negative tears progressed to detachment at follow-

284 Eleven (84.6%) false-negative tears underwent follow-up within days bas

285 To minimize false positive and false negative test results in population-screening assa

286 cal influence on the probability to obtain a false-negative test result.

287 sample dilution increases the likelihood of false-negative test results for individuals with a low v

288 False-negative test results may lead to unnecessary quar

289 polymerase chain reaction testing, although false-negative test results may occur in up to 20% to 67

290 False-negative test results occurred in approximately 11

291 with >= 9 years of undetectable viral load), false-negative test results were found in at least 1 HIV

292 ative diagnostic test results (ie, suspected false-negative test results) compared with a representat

293 form better (in terms of false positives and false negatives) than the vendor-supplied software packa

294 dominal hypertension is responsible for some false negatives to the passive leg raising test.

295 ttenuating the number of false positives and false negatives under high-throughput screening conditio

296 Progenesis QI) allow to decrease the rate of false negative up to 4% (MZmine2).

297 The rates of false positives and of false negatives were computed and only the false positiv

298 d 100% sensitivity and specificity whereas 2 false negatives were identified using the PBP2' latex ag

299 ncy of the Pfhrp2/3 deletion associated with false negatives when using Rapid Diagnostic Tests.

300 evel to individuals' vocal skill may lead to false negatives, which may have largely been the case in